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Abstract
Background: Members of the genus Scedosporium are emerging human pathogens, causing a wide range 
of infections. Their treatment means a challenge for clinicians, mostly because of the low susceptibility 
of these causative agents to conventional antifungal drugs. New alternative therapeutic approaches 
are required for better clinical outcomes. Cysteine and its derivatives alone or in combinations with 
antifungal drugs might have improved antifungal effects against Scedosporium species.
Methods: The in vitro antifungal effects of two cysteine forms and three of their derivatives (i.e., 
D-cysteine, L-cysteine, L-cysteine-methyl ester hydrochloride, N-isobutyryl-D-cysteine, and 
N-isobutyryl-L-cysteine) were determined using the CLSI M38-A2 broth microdilution method. The in 
vitro drug interactions between the most effective cysteine derivatives and some conventional antifungal 
drugs were also investigated using checkerboard assays in case of four clinical isolates.
Results: L-cysteine-methyl ester hydrochloride proved to be the most effective among the investigated 
compounds. N-isobutyryl-L-cysteine exhibited antifungal activity against one Scedosporium aurantiacum 
strain only. D-cysteine, L-cysteine and N-isobutyryl-D-cysteine proved to be ineffective against 
Scedosporium spp. in the investigated concentration range. No significant differences were found in the 
susceptibilities between environmental and clinical isolates. L-cysteine-methyl ester hydrochloride could 
interact synergistically with amphotericin B, caspofungin, terbinafine and voriconazole. Antagonistic 
interactions were not observed between the investigated compounds.
Conclusions: The present study provides an evidence for the in vitro antifungal activity of L-cysteine-
methyl ester hydrochloride and the synergistic interactions between this cysteine derivative and 
conventional antifungal agents. Based on our results, L-cysteine-methyl ester hydrochloride in 
combination with antifungal drugs could be applicable in the treatment of human Scedosporium 
infections in the future. However, further studies are required to clarify the antifungal mechanism of 
L-cysteine-methyl ester hydrochloride and to investigate its activity in vivo.
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Introduction
Scedosporium species are emerging human pathogens, responsible 
for a broad spectrum of infections, including superficial or deep 
localized diseases in immunocompetent hosts, and disseminated 
infections in immunocompromised or in near-drowning patients 
[1]. Scedosporium boydii and Scedosporium apiospermium are mainly 
associated with infections in temperate climates (e.g., Central 
Europe), while Scedosporium aurantiacum and Scedosporium 
prolificans infections are predominant in hot and arid countries (e.g., 
Spain, Australia) [2]. According to a recent clinical study in Spain, 
the members of this genus are the second most frequently isolated 
filamentous fungi from human infections after Aspergillus species [3]. 
The clinical manifestations of Scedosporium infections are very similar 
to those of aspergillosis, fusariosis and other hyalohyphomycosis 
[4]. The proper diagnosis is complicated by the low interspecies 
diversity and high intraspecies variability, especially within the S. 
boydii species complex. However, the accurate identification of 
the causative agent is crucial to find the most effective therapeutic 
approach, since the antifungal susceptibility profile of Scedosporium 
species is different from those of hyaline filamentous fungi, and also 
varies within the genus itself [2]. Another challenge in the treatment 
is the frequently observed antifungal resistance of the Scedosporium 
isolates to conventional antifungal agents [1]. In a consequence 
of these, clinicians have limited options to treat Scedosporium
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infections. Therefore, new therapeutic strategies are required beside of 
the currently available ones.
Cysteine and their derivatives have been previously reported to have 
antifungal activity against different filamentous fungi (Table 1) [5-11]. 
Previously we proved the antifungal activity of N-acetyl-L-cysteine 
against Scedosporium species [12]. D-cysteine (DC), L-cysteine (LC), 
L-cysteine-methyl ester (LCME), N-isobutyryl-D-cysteine (NIDC), 
and N-isobutyryl-L-cysteine (NILC) showed antifungal effect against 
species belonging to Mucorales [6]. LC was reported to inhibit 
spore germination and to cause reduced hyphal growth in different 
filamentous fungi (e.g. dermatohytes, Aspergillus spp., Fusarium spp.) 
[7,8,11].
The aims of the present study were (i) to determine the in vitro 
susceptibility of clinical and environmental Scedosporium isolates 
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to DC, LC and their derivatives, such as LCME, NIDC, and NILC; 
and (ii) to investigate the in vitro combinations of the most effective 
cysteine compound with conventional antifungal agents against 
clinical Scedosporium isolates. developed for the diagnosis of UTIs. 
Rapid biochemical dipstick tests are available and currently used 
as predictors of bacterial UTI, but must often be correlated with 
other testing and clinical information. In many clinical settings, in 
fact, it has been proved that the dipstick urinalysis leads to many 
false positive and negative results when compared with the gold 
standard culture method, demonstrating the low sensitivity and 
positive predictive value [10]. The Micro Biological Survey method 
(MBS) is an alternative method for bacterial counting developed 
and patented by Roma Tre University [11,12]. It is based on a 
colorimetric survey performed in mono-use disposable reaction
vials in which samples can be inoculated without any preliminary 
treatment. The analysis can be carried out using a thermostatic optical
reader that automatically detects the color change. The ease of use 
of the MBS method has been evaluated in a previous study on food 
samples demonstrating the possibility to use it anywhere and without 
the need of an equipped laboratory and specialized personnel [13]. In 
previous studies carried out on artificially contaminated urine samples, 
this method has already been proven to be suitable for the evaluation 
of the bacterial load and the assessment of the susceptibility to a 
panel of antibiotics [14,15]. The present study has been undertaken to 
clinically evaluate the performance and operational characteristics of 
the MBS POCT for the diagnosis and the antibiotic treatment of UTIs. 
The MBS method was also compared with another biochemical rapid 
test for UTI diagnosis, namely the urine dipstick assay [16].
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Cysteine/
derivativesa
Chemical structureb Investigated organisms Antifungal effect/mode of action References
DC
Eutypa lata 50% growth inhibition [5]
Mucorales spp. Reduced hyphal growth, MEC: 0.625-10 mM [6]
Dermatohytes Poor growth
Change in colony morphology
[7]
Microsporum gypseum,
Trichophyton mentagrophytes
MIC: 0.5-0.4% (w/v)
MFC: 0.8-0.9% (w/v)
[8]
Alternaria spp. Inhibited spore germination
Inonotus obliquus Inhibited mycelial growth
Reduced ergosterol production
[9]
LC Aspergillus spp.
Fusarium spp.
MIC: 0.078-0.625% (w/v)
Inhibited conidial germination
May reduce conidial wall permeability to nutrients
[10]
Eutypa lata Inhibited growth, MIC: 10 mM
Modified structural organization of the mycelium 
(complete disorganization of the cell content, nuclear 
degeneration)
[5]
LCME Mucorales spp.
Reduced hyphal growth, MEC: 0.625-10 mM
Change in colony morphology
Inhibited sporangiospore germination
[6]
NIDC Mucorales spp. Reduced hyphal growth, MEC: 0.625-5 mM
[6]
NILC Mucorales spp.
Reduced hyphal growth, MEC: 0.625-10 mM
Change in colony morphology
[6]
Table 1: Overview of the antifungal activity of the tested cysteine forms and their derivatives.
aDC, D-cysteine; LC, L-cysteine; LCME, L-cysteine-methyl ester hydrochloride; NIDC, N-isobutyryl-D-cysteine; NILC, N-isobutyryl-L-cysteine.
bSource: http://www.sigmaaldrich.com/
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Materials and Methods
Strains and culture conditions
Nine Scedosporium isolates derived from different environmental 
and clinical sources were involved in this study (Table 2). Prior to the 
tests, to get the required amount of conidia all the strains were grown 
on malt extract slants (MEA, Biolab, Hungary) for 2 weeks at 30°C. 
Susceptibility tests were performed in RPMI 1640 medium (Sigma-
Aldrich, USA) supplemented with 0.3 g/l L-glutamine and buffered 
to pH 7.0 with 0.165 M 4-morpholinopropanesulfonic acid (Sigma-
Aldrich, USA) and were incubated at 37°C for 72 hours.
Microdilution tests
The susceptibility of Scedosporium isolates to cysteine forms and 
their derivatives were determined following the slightly modified 
instructions of the Clinical and Laboratory Standards Institute's 
M38-A2 broth microdilution method [13]. Minimum inhibitory 
concentration (MIC) was defined as the lowest concentration of a 
drug which was required for the total growth inhibition of a certain 
isolate after 72 hours-long incubation. Modifications connected to 
stock solution and inoculum preparation were detailed previously 
[14]. We evaluated the antifungal effect of five compounds: DC, 
LC, LCME, NIDC, and NILC (Sigma-Aldrich, USA). The final drug 
concentrations in the tests ranged from 64 to 1024 µg/ml.
Drug interactions between LCME and conventional antifungal 
agents (i.e., amphotericin B, AMB; caspofungin, CSP; terbinafine, 
TRB; and voriconazole, VRC) were investigated against the four 
clinical isolates using the checkerboard microdilution method [15]. 
The final LCME concentrations ranged from 64 to 2048 µg/ml. The 
final concentrations of the antifungal drugs were between 0.25 and 
128 µg/ml. Fractional inhibitory concentration indexes (FICIs) were 
calculated to demonstrate the type of interaction between the paired 
combinations of compounds [16]. For these calculations, the MICs 
of antifungals have been already determined in a recent study of our 
research group [14]. Synergism was defined as FICI≤0.5, indifference 
as 0.5<FICI≤4 and antagonism was defined when FICI>4 [17].
Both single and combination tests were performed in three 
replicates.
Results and Discussion
We evaluated the antifungal effect of two cysteine forms, LC 
and DC, and their derivatives against nine Scedosporium isolates. 
The MICs were in the range of 512 - >1024 µg/ml (Table 2). LCME 
proved to be most effective among the investigated compounds with 
a MIC range of 512 - >1024 µg/ml. It demonstrated similar antifungal 
activity against the tested isolates (512 - 1024 µg/ml) except for P. 
ellipsoidea CBS 301.79 strain where the MIC was >1024 µg/ml. DC, 
LC and NIDC were ineffective against the Scedosporium isolates in 
the investigated concentration range (MIC: >1024 µg/ml). While 
NILC proved to be active against one strain only, S. aurantiacum CBS 
116910 (MIC: 1024 µg/ml). Differences between the susceptibilities 
of environmental and clinical isolates to the investigated compounds 
were not observed.
The antifungal activity of cysteine and its derivatives against 
Scedosporium species has not been investigated yet. The MICs 
observed in this study are comparable to previously reported data 
against other fungal species. The in vitro inhibitory effect of DC was 
proved previously against Eutypa lata and different Mucorales species. 
It caused reduced hyphal growth in a concentration of 0.625 - 10 mM 
(~ 75 - 1200 µg/ml) [5,6]. The antifungal effect of LC was reported 
against different filamentous fungi: dermatophytes, Alternaria spp., 
Aspergillus spp., Eutypa lata, Fusarium spp., and Inonotus obliquus [5-
11]. Our previous publication showed the antifungal effect of LCME, 
NIDC, and NILC against Mucorales species: the MEC values were 
between 0.625 and 10 mM (~ 100 - 1700 µg/ml at LCME; ~ 60 - 1000 
µg/ml at NIDC and NILC) [6]. Beside the reduced hyphal growth, 
LCME inhibited the germination of sporangiospores, while the 
presence of NILC in the culture media led to changes in the colony 
morphology [6]. The mode of action of cysteine and their derivatives 
has not been clarified yet. Kahlos and Tikka [10] observed that LC 
reduced the ergosterol production of Inonotus ubliquus. Octave et al. 
[5] reported the complete structural disorganization of the mycelia 
of Eutypa lata. According to Daigle and Cotty [9] the mercaptan 
and amino groups of LC were essential to the inhibition of conidial 
germination.
In the combination tests, the in vitro interactions between the 
most effective non-antifungal agent, LCME and four conventional
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Species (Strain numbera) Source Mean MICs of cysteine and its derivativesb (µg/ml)
DC LC LCME NIDC NILC
S. aurantiacum (CBS 116910) Wound exudate/Spain >1024 >1024 512 >1024 1024
S. aurantiacum (CBS 136046) Human lung/Australia >1024 >1024 1024 >1024 >1024
S. aurantiacum (CBS 136047) Soil/Australia >1024 >1024 1024 >1024 >1024
S. aurantiacum (CBS 136049) Soil/Austria >1024 >1024 1024 >1024 >1024
S. boydii (CBS 117410) Soil/Spain >1024 >1024 1024 >1024 >1024
S. boydii (CBS 117432) Sputum/France >1024 >1024 1024 >1024 >1024
S. boydii (CBS 120157) Human lung/France >1024 >1024 1024 >1024 >1024
P. angusta (CBS 254.72) Sewage/USA >1024 >1024 1024 >1024 >1024
P. ellipsoidea (CBS 301.79) Dung/The Netherlands >1024 >1024 >1024 >1024 >1024
MIC range >1024 >1024 512 - >1024 >1024 1024 - >1024
Table 2 The antifungal activity of cysteine and its derivatives against Scedosporium isolates.
aCBS, Centraalbureau voor Schimmelcultures, Utrecht, The Netherlands. 
bDC, D-cysteine; LC, L-cysteine; LCME, L-cysteine-methyl ester hydrochloride; NIDC, N-isobutyryl-D-cysteine; NILC, N-isobutyryl-L-cysteine.
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antifungal drugs were evaluated. These results are summarized in 
Table 3. We revealed no antagonistic interaction for LCME with any 
of the antifungal drugs. Between LCME and AMB, and LCME and 
TRB only synergistic interactions were observed (FICILCME+AMB: 0.06 - 
0.13, FICILCME+TRB: 0.09 - 0.16). For S. aurantiacum CBS 116910 strain, 
the drug interaction between LCME and CSP and between LCME 
and VRC proved to be indifferent. However, we found synergistic 
interaction in all other cases between these compounds (FICILCME+CSP: 
0.13 - 0.63, FICILCME+VRC: 0.13 - 1.00) (Table 3). Previously, we 
investigated the in vitro combinations of another L-cysteine derivative, 
N-acetyl-cysteine with AMB, CSP, TRB, and VRC [12]. Similarly, 
synergistic interactions were revealed predominantly between the 
investigated agents and antagonistic interactions were not registered.
When used alone, the MIC range of LCME were 512 - 1024 µg/
ml, but in combination with AMB, CSP, TRB, and VRC, these values 
reduced to 64 µg/ml, 64 - 128 µg/ml, 64 µg/ml, and 64 - 256 µg/ml, 
respectively. Compared to the single use, the MICs of antifungal 
agents were also decreased in the combination tests. The previously 
determined MIC ranges of AMB, CSP, TRB, and VRC were 8 - 128 
µg/ml, 32 - 64 µg/ml, 128 µg/ml and 8 - 64 µg/ml, respectively [14]. 
In combination with LCME, the MIC ranges of AMB, CSP, TRB, and 
VRC were decreased to 0.25 - 4 µg/ml, 0.125 - 16 µg/ml, 4 - 8 µg/ml, 
and 0.125 - 4 µg/ml, respectively (Table 3). Compared to the single 
use, the MIC values of antifungal drugs in the combination tests could 
be decreased to their achievable therapeutic plasma concentrations in 
several cases [18-21].
Conclusions 
This is the first study investigating the activity of cysteine 
derivatives against Scedosporium species and the first report of the 
in vitro antifungal effect of LCME and its synergistic interactions 
with conventional antifungal agents against Scedosporium isolates.
According to our results, LCME alone or in combination with other 
drugs might be useful for the treatment of human Scedosporium 
infections. However, further studies are required to investigate 
the antifungal mechanism of LCME and its pharmacokinetic and 
pharmacodynamic properties.
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Isolatea Mean MIC (µg/ml)b FICIc Interactiond
LCMEalone LCMEcomb AMBalone* AMBcomb
S. aurantiacum (CBS 116910) 512 64 128 1 0.13 S
S. aurantiacum (CBS 136046) 1024 64 128 4 0.09 S
S. boydii (CBS 117432) 1024 64 128 0.25 0.06 S
S. boydii (CBS 120157) 1024 64 64 2 0.09 S
LCMEalone LCMEcomb CSPalone* CSPcomb
S. aurantiacum (CBS 116910) 512 64 32 16 0.63 NI
S. aurantiacum (CBS 136046) 1024 128 64 0.125 0.13 S
S. boydii (CBS 117432) 1024 64 64 8 0.19 S
S. boydii (CBS 120157) 1024 128 32 0.125 0.13 S
LCMEalone LCMEcomb TRBalone* TRBcomb
S. aurantiacum (CBS 116910) 512 64 128 4 0.16 S
S. aurantiacum (CBS 136046) 1024 64 128 4 0.09 S
S. boydii (CBS 117432) 1024 64 128 4 0.09 S
S. boydii (CBS 120157) 1024 64 128 8 0.13 S
LCMEalone LCMEcomb VRCalone* VRCcomb
S. aurantiacum (CBS 116910) 512 256 8 4 1.00 NI
S. aurantiacum (CBS 136046) 1024 128 32 0.125 0.13 S
S. boydii (CBS 117432) 1024 64 16 4 0.31 S
S. boydii (CBS 120157) 1024 64 16 1 0.13 S
Table 3: The combination test results of LCME and conventional antifungal drugs against clinical Scedosporium isolates.
aCBS, Centraalbureau voor Schimmelcultures, Utrecht, The Netherlands.
bLCMEalone, AMBalone, CSPalone, TRBalone and VRCalone, mean MICs of L-cysteine methyl ester hydrochloride, amphotericin B, caspofungin, terbinafine 
and voriconazole, respectively, when applied alone; LCMEcomb, AMBcomb, CSPcomb, TRBcomb and VRCcomb, mean MICs of L-cysteine methyl ester 
hydrochloride, amphotericin B, caspofungin, terbinafine and voriconazole, respectively, when applied in combination.
cFICI, fractional inhibitory concentration index value
dNI, no interaction (0.5 < FICI ≤ 4); S, synergism (FICI ≤ 0.5) [17].
*The MICs of AMB, CSP, TRB and VRC were determined in a previous study of our research group [14].
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